Novaremed AG: Novaremed Enters Into an Exclusive Option and

NeuroFront receives an exclusive option for an exclusive license to develop, commercialize and manufacture NRD.E1, Novaremed's first-in-class, non-opioid investigational drug for the treatment of

Related Keywords

China , Taiwan , Hong Kong , Singapore , Macau , Mark Altmeyer , Kostenloser Wertpapierhandel , June Yan , Isaac Kobrin , Clinical Pharmacology In Drug Development , Metys Pharmaceuticals Ag Switzerland , Company Investment House , Novaremed Ltd Israel , National Institutes Of Health , Neurofront Therapeutics Hong Kong , Nan Fung Life Sciences , Greater China , Neurofront Therapeutics , Mainland China , Executive Chairman , Track Designation , Company Investment , Fast Track Designation , National Institutes , Help End Long Term Addiction , Venture Partners China , Novaremed Ltd , Metys Pharmaceuticals , Drug Development , Executive Member , Novaremed , Centers , Into , Exclusive , Option , License , Agreement , Ith , Eurofront , Opioid , Neuropathic , Rain , Treatment , Greater ,